Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
25.43
-0.75 (-2.86%)
Nov 20, 2024, 4:00 PM EST - Market closed
Enliven Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 21.13 | 17.66 | 7.77 | 4.29 | 1.08 |
| Research & Development | 77.96 | 64.57 | 31.02 | 20.47 | 8.24 |
| Operating Expenses | 99.09 | 82.23 | 38.79 | 24.76 | 9.32 |
| Operating Income | -99.09 | -82.23 | -38.79 | -24.76 | -9.32 |
| Interest & Investment Income | 14.54 | 11.97 | 1.13 | 0.02 | 0.03 |
| Other Non Operating Income (Expenses) | 0.86 | -0.02 | - | - | - |
| EBT Excluding Unusual Items | -83.68 | -70.28 | -37.66 | -24.74 | -9.29 |
| Merger & Restructuring Charges | -1.3 | -1.3 | - | - | - |
| Other Unusual Items | - | - | - | - | -9.68 |
| Pretax Income | -84.98 | -71.58 | -37.66 | -24.74 | -18.97 |
| Net Income | -85.21 | -71.58 | -37.66 | -24.74 | -18.97 |
| Net Income to Common | -85.21 | -71.58 | -37.66 | -24.74 | -18.97 |
| Shares Outstanding (Basic) | 45 | 36 | 3 | 8 | 5 |
| Shares Outstanding (Diluted) | 45 | 36 | 3 | 8 | 5 |
| Shares Change (YoY) | 72.23% | 1037.74% | -60.02% | 56.70% | - |
| EPS (Basic) | -1.90 | -2.01 | -12.05 | -3.17 | -3.80 |
| EPS (Diluted) | -1.90 | -2.01 | -12.05 | -3.17 | -3.80 |
| Free Cash Flow | -68.53 | -61.42 | -32.69 | -19.33 | -8.99 |
| Free Cash Flow Per Share | -1.53 | -1.73 | -10.46 | -2.47 | -1.80 |
| EBITDA | -98.77 | -81.93 | -38.58 | -24.65 | -9.27 |
| D&A For EBITDA | 0.32 | 0.3 | 0.22 | 0.12 | 0.05 |
| EBIT | -99.09 | -82.23 | -38.79 | -24.76 | -9.32 |
Source: S&P Capital IQ. Standard template.
Financial Sources.